



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|---|------------|
| Summary for ARTG Entry: | 372990 | Ubiq-Evail |
| ARTG entry for | Medicine Listed | |
| Sponsor | Designs For Health Pty Ltd | |
| Postal Address | 1 / 418 Pittwater Road, North Manly, NSW, 2100 Australia | |
| ARTG Start Date | 17/08/2021 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Ubiq-Evail

| | | | |
|---------------------|-------------------------|-----------------------|------------|
| Product Type | Single Medicine Product | Effective Date | 20/07/2023 |
|---------------------|-------------------------|-----------------------|------------|

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support energy levels
Maintain/support energy production
Relieve weariness/tiredness/fatigue/feeling of weakness
Anti-inflammatory/relieve inflammation
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function
Maintain/support heart health
Maintain/support blood vessel health

Indication Requirements

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.
Product presentation must not imply or refer to serious cardiovascular conditions.
Product presentation must not imply or refer to chronic fatigue syndrome.
Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.
Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not take while on warfarin therapy without medical advice.

Additional Product information



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

| Pack Size/Poison information | |
|---------------------------------------|-----------------|
| Pack Size | Poison Schedule |
| Components | |
| 1 . Formulation 1 | |
| Dosage Form | Capsule, soft |
| Route of Administration | Oral |
| Visual Identification | |
| Active Ingredients | |
| ubiquinol-10 | 150 mg |
| Other Ingredients (Excipients) | |
| annatto | |
| Bixa orellana | |
| Gelatin | |
| glycerol | |
| medium chain triglycerides | |
| purified water | |
| Quillaia Powder | |

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary